SMC Approves First Subcutaneous Bispecific Treatment Option Tepkinly[® ]▼(epcoritamab) for Adults with an Aggressive Form of Blood Cancer After Two or More Lines of Systemic Therapy
· For the first time, adults in Scotland with diffuse large B-cell lymphoma (DLBCL) whose cancer has returned or not responded to at least two prior treatments, will have access to a subcutaneous bispecific treatment option administered as an injection under the skin[1,2]. · Epcoritamab is part of a new class of therapies called bispecific antibodies. Bispecific antibodies help the body’s immune system to attack and destroy cancerous cells[3]. · DLBCL is an aggressive blood cancer, with approximately 430 adults diagnosed with the disease in Scotland each year. For patients whose